Deutsch English Français

Contact

EP1973549

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1973549

EP1973549 - METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON [Right-click to bookmark this link]
Status	Patent revoked Status updated on 23.06.2023 Database last updated on 03.04.2025
Most recent event Tooltip	23.06.2023	Revocation of patent	published on 26.07.2023 [2023/30]
	23.06.2023	New entry: Despatch of communication that patent is revoked
Applicant(s)	For all designated states Vifor (International) AG Rechenstraße 37 9001 St. Gallen / CH
	[2016/46]
Former [2016/29]	For all designated states Luitpold Pharmaceuticals, Inc. One Luitpold Drive Shirley 11967 / US
Former [2008/40]	For all designated states Luitpold Pharmaceuticals, Inc. One Luitpold Drive Shirley 11967 / US
Inventor(s)	01 / HELENEK, Mary, Jane 13 Evans Drive Brookville, NY 11545 / US
	02 / TOKARS, Marc, L. 202 Farmingdale Drive Douglassville, PA 19618 / US
	03 / LAWRENCE, Richard, P. 94 Young Avenue Calverton, NY 11933 / US
	[2008/40]
Representative(s)	Gille Hrabal Partnerschaftsgesellschaft mbB Patentanwälte Postfach 18 04 09 40571 Düsseldorf / DE
	[N/P]
Former [2013/19]	Teuten, Andrew John, et al Sagittarius IP Three Globeside Fieldhouse Lane Marlow, Buckinghamshire SL7 1HZ / GB
Former [2013/07]	Sagittarius IP Three Globeside Fieldhouse Lane Marlow Buckinghamshire SL7 1HZ / GB
Former [2008/40]	Teuten, Andrew John Sagittarius Intellectual Property Consultants Ltd Taylor House 39 High Street Marlow, Bucks. SL7 1AF / GB
Application number, filing date	07716309.5	08.01.2007
	[2008/40]
	WO2007US00176
Priority number, date	US20060757119P	06.01.2006 Original published format: US 757119 P
	[2013/32]
Former [2008/40]	US20060757119P	06.01.2006
	US20070620986	08.01.2007
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2007081744
	Date:	19.07.2007
	Language:	EN
	[2007/29]
	Type:	A2 Application without search report
	No.:	EP1973549
	Date:	01.10.2008
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 19.07.2007 takes the place of the publication of the European patent application.
	[2008/40]
	Type:	B1 Patent specification
	No.:	EP1973549
	Date:	20.07.2016
	Language:	EN
	[2016/29]
Search report(s)	International search report - published on:	US	08.11.2007
	(Supplementary) European search report - dispatched on:	EP	21.10.2009
Classification	IPC:	A61K31/715, A61P7/06	[2009/47]
	CPC:	A61K31/7135 (EP,KR,US); A61K31/715 (EP,KR,US); A61K31/721 (EP,KR,US); A61K33/26 (KR); A61K9/0019 (KR); A61P1/00 (EP); (+) A61P13/12 (EP); A61P19/02 (EP); A61P3/00 (EP); A61P35/00 (EP); A61P35/02 (EP); A61P7/06 (EP); A61P9/04 (EP); C07H23/00 (EP,KR,US) (-)
	Former IPC [2008/40]	A61K31/715
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2016/29]
Former [2008/40]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	RS	Not yet paid
Title	German:	VERFAHREN UND ZUSAMMENSETZUNGEN ZUR EISENVERABREICHUNG	[2008/40]
	English:	METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON	[2008/40]
	French:	MÉTHODES ET COMPOSITIONS POUR L'ADMINISTRATION DE FER	[2008/40]
Entry into regional phase	16.07.2008	National basic fee paid
	16.07.2008	Search fee paid
	16.07.2008	Designation fee(s) paid
	16.07.2008	Examination fee paid
Examination procedure	16.07.2008	Examination requested [2008/40]
	24.12.2009	Amendment by applicant (claims and/or description)
	10.05.2011	Despatch of a communication from the examining division (Time limit: M06)
	09.11.2011	Reply to a communication from the examining division
	04.06.2012	Despatch of a communication from the examining division (Time limit: M06)
	14.12.2012	Reply to a communication from the examining division
	05.07.2013	Despatch of a communication from the examining division (Time limit: M06)
	15.01.2014	Reply to a communication from the examining division
	31.10.2014	Observations by third parties
	12.11.2015	Observations by third parties
	27.11.2015	Cancellation of oral proceeding that was planned for 30.11.2015
	30.11.2015	Date of oral proceedings (cancelled)
	08.01.2016	Communication of intention to grant the patent
	17.05.2016	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	17.05.2016	Fee for grant paid
	17.05.2016	Fee for publishing/printing paid
	08.06.2016	Information about intention to grant a patent
	08.06.2016	Receipt of the translation of the claim(s)
	23.07.2018	Observations by third parties
Divisional application(s)	EP13166988.9 / EP2626074
	EP16172826.6 / EP3081219
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.05.2011
Opposition(s)	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		[N/P]
	Former [2021/49]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF 1 City Walk Leeds LS11 9DX / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2021/15]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF 1 City Walk Leeds LS11 9DX / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2021/03]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF 1 City Walk Leeds LS11 9DX / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2020/30]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF 1 City Walk Leeds LS11 9DX / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2020/13]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2019/18]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
	Former [2019/10]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative FRKelly 27 Clyde Road Dublin D04 F838 / IE
	Former [2017/37]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Washbrook, Michael James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / DE
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative FRKelly 27 Clyde Road Dublin D04 F838 / IE
	Former [2017/22]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
		03 18.04.2017 24.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		04 19.04.2017 24.04.2017 ADMISSIBLE HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
		05 20.04.2017 26.04.2017 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 20.04.2017 26.04.2017 ADMISSIBLE Taylor Wessing LLP 5 New Street Square London EC4A 3TW / GB Opponent's representative Washbrook, Michael James Taylor Wessing LLP 5 New Street Square London EC4A 3TW / DE
		07 20.04.2017 26.04.2017 ADMISSIBLE Generics [U.K.] Limited Station Close Potters Bar Herfordshire EN6 1TL / GB Opponent's representative McNally, Roisin FRKelly 27 Clyde Road Dublin D04 F838 / IE
	Former [2017/21]
	Opponent(s)	01 10.04.2017 19.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		02 13.04.2017 20.04.2017 ADMISSIBLE Pharmacosmos Holding A/S Rørvangsvej 30 Postboks 40 4300 Holbæk / DK Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
		03 18.04.2017 ADMISSIBLE TEVA PHARMACEUTICAL INDUSTRIES, LTD. 5 Basel Street, P.O. Box 3190 49131 Petach-Tikva / IL Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		04 19.04.2017 HGF Limited 1 City Walk Leeds Yorkshire LS11 9DX / GB Opponent's representative HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
	Former [2017/20]
	Opponent(s)	01 10.04.2017 ADMISSIBLE Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastrasse 30 81925 München / DE Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	26.05.2017	Invitation to proprietor to file observations on the notice of opposition
	02.02.2018	Reply of patent proprietor to notice(s) of opposition
	30.01.2019	Date of oral proceedings
	28.02.2019	Despatch of interlocutory decision in opposition
	28.02.2019	Despatch of minutes of oral proceedings
	24.05.2023	Legal effect of revocation of patent [2023/30]
	07.06.2023	Despatch of communication that the patent will be revoked
Appeal following opposition	10.05.2019	Appeal received No. T1139/19
	10.07.2019	Statement of grounds filed
	24.05.2023	Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
	07.06.2023	Despatch of the decision of the Board of Appeal
	03.05.2019	Appeal received No. T1139/19
	08.07.2019	Statement of grounds filed
	24.05.2023	Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
	07.06.2023	Despatch of the decision of the Board of Appeal
	26.04.2019	Appeal received No. T1139/19
	05.07.2019	Statement of grounds filed
	24.05.2023	Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
	07.06.2023	Despatch of the decision of the Board of Appeal
	23.04.2019	Appeal received No. T1139/19
	02.07.2019	Statement of grounds filed
	24.05.2023	Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
	07.06.2023	Despatch of the decision of the Board of Appeal
	07.05.2019	Appeal received No. T1139/19
	24.05.2023	Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
	07.06.2023	Despatch of the decision of the Board of Appeal
	02.05.2019	Appeal received No. T1139/19
	24.05.2023	Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
	07.06.2023	Despatch of the decision of the Board of Appeal
	12.04.2019	Appeal received No. T1139/19
	24.05.2023	Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
	07.06.2023	Despatch of the decision of the Board of Appeal
	24.05.2023	Date of oral proceedings
Fees paid	Renewal fee
	16.07.2008	Renewal fee patent year 03
	28.01.2010	Renewal fee patent year 04
	14.01.2011	Renewal fee patent year 05
	11.01.2012	Renewal fee patent year 06
	10.01.2013	Renewal fee patent year 07
	21.01.2014	Renewal fee patent year 08
	13.01.2015	Renewal fee patent year 09
	11.01.2016	Renewal fee patent year 10
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO9711711 (LUITPOLD PHARM INC [US]) [X] 1-3,7,9,15,16 * claims 1,10,16,17 * * table 2 *;
		[X]US6599498 (GROMAN ERNEST V [US], et al) [X] 1-4,7,9,10,12,15,16 * claims 1,23 * * column 12, line 11 - line 17 *;
		[X]WO2004037865 (VIFOR INT AG [CH], et al) [X] 1-3,7-9,15,16 * claims 1,7-9 * * page 7, lines 5,10 * * page 5, line 1 - line 2 * * page 8, line 5 - line 6 *;
		[E]WO2007023154 (VIFOR INT AG [CH], et al) [E] 1-4,7-10,15,16 * claims 1-9 *;
		[X] - BESHARA SOHEIR; SORENSEN JENS; LUBBERINK MARK; TOLMACHEV VLADIMIR; LANGSTROM BENGT; ANTONI GUNNAR; DANIELSON BO G; LUNDQVIST HANS, "Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography", BRITISH JOURNAL OF HAEMATOLOGY, (200303), vol. 120, no. 5, pages 853 - 859, XP002549269 [X] 1-18 * page 857, column R, paragraph 3 * * table I * DOI: http://dx.doi.org/10.1046/j.1365-2141.2003.03590.x
		[X] - LANDRY ROBERT; JACOBS PAULA M; DAVIS ROBERT; SHENOUDA MAGDY; BOLTON W KLINE, "Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients", AMERICAN JOURNAL OF NEPHROLOGY, (2005), vol. 25, no. 4, pages 400 - 410, XP009123870 [X] 1-10,12,14-16 * page 400, abstract * DOI: http://dx.doi.org/10.1159/000087212
		[X] - SPINOWITZ BRUCE S; SCHWENK MICHAEL H; JACOBS PAULA M; BOLTON W KLINE; KAPLAN MARK R; CHARYTAN CHAIM; GALLER MARILYN, "The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients", KIDNEY INTERNATIONAL, (200510), vol. 68, no. 4, pages 1801 - 1807, XP002549270 [X] 1-4,7,9,10,12,15,16 * page 1801, left-hand column, Conclusion * DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.00598.x
	International search	[X]US2004180849 (HELENEK MARY JANE [US], et al)
	Examination	- MACDOUGALL I C, "Strategies for iron supplementation: Oral versus intravenous", KIDNEY INTERNATIONAL, (1999), vol. 55, no. 69Suppl., pages S61 - S66
		- AUERBACH M & AL TALIB K, "Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease", KIDNEY INTERNATIONAL, (2008), vol. 73, pages 528 - 530
		- GEISSER P, BAER M & SCHAUB E, "Structure / Histotoxicity Relationship of Parenteral Iron Preparations", ARZNEIM.-FORSCH./DRUG RES., (1992), vol. 42, no. 12, pages 1439 - 1452
		- JAHN M R ET AL., "A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, (2011), vol. 78, pages 480 - 491
		- MACDOUGALL I C, GEISSER P, "Use of intravenous supplementation in chronic kidney disease", IRANIAN JOURNAL OF KIDNEY DISEASES, (201301), vol. 7, no. 1, pages 9 - 22
		- MARCHASIN S & WALLERSTEIN R O, "The treatment of iron-deficiency anemia with intravenous iron dextran", BLOOD, (1964), vol. 23, no. 3, pages 354 - 358
	other	US5624668
		- GEISSER et al., "STRUCTURE/HISTOTOXICITY RELATIONSHIP OF PARENTERAL IRON PREPARATIONS", Arzneimittelforschung, (19920000), vol. 42, no. 12, pages 1439 - 1452, XP001121211
	Opposition	WO9711711
		US6599498
		CA2493806
		WO2004037865
		US2004180849
		US2003232084
		WO2007081744
		WO0246241
		US7612109
		US2006116349
		US3639588
		- PREUSSER et al., "Effects of intravenous ABT-870...", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, (20050000), vol. 32, no. 12, pages 1020 - 1026, XP055370620
		- DR BARBARA VON EISENHART ROTHE, "The spoken word shall count", Galenica Speech of Press Conference, (20050412), XP055374978
		- BESHARA et al., "Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography", BRITISH JOURNAL OF HAEMATOLOGY, (20030300), vol. 120, no. 5, pages 853 - 859, XP002549269 DOI: http://dx.doi.org/10.1046/j.1365-2141.2003.03590.x
		- LANDRY et al., "Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients", AMERICAN JOURNAL OF NEPHROLOGY, (20050000), vol. 25, no. 4, pages 400 - 410, XP009123870 DOI: http://dx.doi.org/10.1159/000087212
		- SPINOWITZ et al., "The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients", KIDNEY INTERNATIONAL, (20051000), vol. 68, no. 4, pages 1801 - 1807, XP002549270 DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.00598.x
		- MARCHASIN et al., "The treatment of iron-deficiency anaemia with intravenous iron dextran", Blood, (19640000), vol. 23, no. 3, pages 354 - 358, XP055183808
		- LANDRY ROBERT et al, "Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients", Am. J. Nephrol., (20051000), vol. 25, no. 4, pages 400 - 410, XP009123870 DOI: http://dx.doi.org/10.1159/000087212
		- "Injections", Artur Burger et al, Hunnius Pharmazeutisches Wörterbuch, WdeG, (19980000), page 710, XP055374773
		- ARONOFF G.R., "Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols", Journal of the American Society of Nephrology, (20040000), vol. 15, no. Suppl 2, pages 599 - 5106, XP055374940 DOI: http://dx.doi.org/10.1097/01.ASN.0000143815.15433.87
		- MARCHASIN et al., "The treatment of Iron-Deficiency Anemia with Intraveneous Iron Dextratf", Blood, (19640000), vol. 23, no. 3, pages 354 - 358, XP055183808
		- SPINOWITZ et al., "The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients", Kidney International, (20051000), vol. 68, no. 4, pages 1801 - 1807, XP002549270 DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.00598.x
		- VAN WYCK, "Labile Iron., Manifestations and Clinical Implications", Journal of the American Society of Nephrology, (20040000), vol. 15, no. Suppl 2, pages S107 - S111, XP055374947 DOI: http://dx.doi.org/10.1097/01.ASN.0000143816.04446.4C
		- GUPTE et al., "Iron Deficiency Anemia: Management and Prevention in Children", Science, (20011000), vol. 3, no. 4, pages 160 - 165, XP055374954
		- Fritz Hirsbrunner, "Venofer® approved by FDA ahead of company expectations for use in USA for treatment of iron deficiency anemia in pre-dialysis patients", GALENICA PRESS RELEASE, (20050620), XP055374967
		- DANIELSON, "Structure, Chemistry, and Pharmacokinetics of Intravenous Iron Agents", Journal of the American Society of Nephrology, (20041200), vol. 15, no. Suppl 2, pages S93 - S98, XP002759508 DOI: http://dx.doi.org/10.1097/01.ASN.0000143814.49713.C5
		- VAN WYCK et al., "A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD", Kidney International, (20051200), vol. 68, no. 6, pages 2846 - 2856, XP055374958 DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.00758.x
		- JAHN et al., "A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications", European Journal of Pharmaceutics and Biopharmaceutics, (20110800), vol. 78, no. 3, pages 480 - 491, XP028241966 DOI: http://dx.doi.org/10.1016/j.ejpb.2011.03.016
		- DR. BARBARA VON EISENHART ROTHE, "The spoken word shall count", GALENICA SPEECH OF PRESS CONFERENCE 5005;, (20050412), XP055374978
		- BRUCE S. SPINOWITZ;, "The safety and Efficacy of Ferumoxytol therapy in anemic chronic kidney disease patients", Kidney International, (20050000), vol. 68, pages 1801 - 1807, XP002549270 DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.00598.x
		- VAN ZYL-SMIT et al., "Experience with the Use of an Iron polymaltose (Dextrin) Complex Given by Single Total Dose Infusion to Stable Chronic Haemodialysis Patients;", NEPHRON, (20020000), vol. 92, pages 316 - 323, XP055375076 DOI: http://dx.doi.org/10.1159/000063300
		- SIDNEY MARCHASIN et al., "The Treatment of Iron-Deficiency Anemia with Intravenous Iron Dextran;", Blood, (19640300), vol. 23, no. 3, pages 354 - 358, XP055183808
		- SINGH et al., "NPL A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy.", Eur . J Haematol., (19980200), vol. 60, no. 2, pages 119 - 124, XP055375081 DOI: http://dx.doi.org/10.1111/j.1600-0609.1998.tb01008.x
		- "Chapters 7, 9, 10 and 11", ROBERT R. CRICHTON et al., Iron Therapy with Special Emphasis on Intravenous Administration, UNI-MED, (20050000), pages 6pp, 9 - 10, 57 - 72, 81 - 96, XP055375089
		- GEISSER et al., "STRUCTURE/HISTOTOXICITY RELATIONSHIP OF PARENTERAL IRON PREPARATIONS", ARZNEIMITTEL FORSCHUNG/ DRUG RESEARCH, (19920000), vol. 42, no. 12, pages 1439 - 1452, XP001121211
		- VAN WYCK, "Labile iron: manifestations and clinical implications", J. Am. Soc. Nephrology, (20040000), vol. 15, pages S107 - S111, XP055374947 DOI: http://dx.doi.org/10.1097/01.ASN.0000143816.04446.4C
		- Dr Barbara Von Eisenhart Rothe, "The spoken word shall count", Galenica Speech of Press Conference, (20050412), XP055374978
		- "UBS Investment Research - Galenica", UBS report on Galenica's financial results, (20040415), pages 1 - 15, XP055375093
		- MANLEY et al., "Determination of VIT 45 (IND#63,243 - American Regent) removal by closed loop in vitro hemodialysis system", The international Journal of Artificial Organs, (20061100), vol. 29, no. 11, pages 1062 - 1066, XP055375097 DOI: http://dx.doi.org/10.1177/039139880602901106
		- MARCHASIN et al., "The Treatment of Iron-Deficiency Anemia with Intravenous Iron Dextran", Blood, (19640000), vol. 23, no. 3, pages 354 - 358, XP055183808
		- PREUSSER et al., "Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents", Clinical and Experimental Pharmacology and Physiology, (20050000), vol. 32, pages 1020 - 1026, XP055370620
		- "Promit® dextran I", Consumer Medicine Information for Promit®, (20050400), pages 1 - 2, XP055375103
		- "Evaluation of the safety, tolerability and pharmacokinetic profiles of single rising doses and increasing administration rates of ABT-870 in ESRD subjects on chronic hemodialysis with iron deficiency anemia", Research Subject Information and Consent Form, (20040430), pages 1 - 10, XP055375111
		- SPINOWITZ et al., "The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients", Kidney International, (20050000), vol. 68, pages 1801 - 1807, XP002549270 DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.00598.x
		- SEID et al., "Safety Profile of Iron Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia.", Blood, (20060000), vol. 108, no. 11, page 3739, XP055383843
		- "Eefficient Anemia Treatment with Large Intravenous Iron Doses", PASCHEN, Geburtshilfe und Frauenheilkunde, (19490000), vol. 9, pages 604 - 616, XP055383855
		- NISSIM, "DEPOSITION OF IRON IN THE TESTES AFTER ADMINISTRATION OF AN IRON-DEXTRAN COMPLEX", Lancet, (19550000), vol. 268, pages 701 - 702, XP055383860 DOI: http://dx.doi.org/10.1016/S0140-6736(55)91068-0
		- DANIELSON, "Structure, chemistry, and pharmacokinetics of intravenous iron agents", J. Am. Soc. Nephrol., (20040000), vol. 15, pages 893 - 898, XP002759508 DOI: http://dx.doi.org/10.1097/01.ASN.0000143814.49713.C5
		- SPINOWITZ et al., "The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients", Kidney Int., (20050000), vol. 68, pages 1801 - 1807, XP002549270 DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.00598.x
		- MCCURDY et al., "Parenteral Iron Therapy : With Special Reference to a New Preparation for Intramuscular Injection", New Engl. J. Med., (19570000), vol. 257, no. 24, pages 1147 - 1153
		- BESHARA et al., "Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography.", Brit. J. Haematol., (20030000), vol. 120, pages 853 - 89, XP002549269 DOI: http://dx.doi.org/10.1046/j.1365-2141.2003.03590.x
		- MARCHASIN et al., The treatment of iron-deficiency anemia with intravenous dextran, (19640000), vol. 23, no. 3, pages 354 - 358, XP055183808
		- PREUSSER et al., "Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents", Clin Exp Pharmacol Physiol., (20050000), vol. 32, no. 12, pages 1020 - 1026, XP055370620

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 35p